School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons, Dublin, Ireland.
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland.
Health Expect. 2024 Feb;27(1):e13962. doi: 10.1111/hex.13962.
Many individuals worldwide continue to take benzodiazepine receptor agonists (BZRAs) long term (≥3 months). The aim of this study was to conduct a content analysis of the views and experiences of discontinuing long-term BZRA use as documented in the free-text responses of respondents to an online questionnaire examining mediators of behaviour change relating to the discontinuation of long-term BZRA use.
The questionnaire was disseminated via online BZRA support groups to community-based adults with either current or previous experience of long-term BZRA use. The four free-text questions focused on (1) barriers and (2) facilitators to discontinuing BZRA use; (3) additional supports required to discontinue BZRA use; and (4) additional comments regarding BZRA use. Response data were analysed using summative content analysis.
The most commonly reported barrier to BZRA discontinuation related to the consequences of stopping the medication, including withdrawal symptoms and the possibility of return of the original symptoms. The most common facilitator that respondents reported would help them in discontinuing BZRA use was support, primarily from medical professionals. Many respondents reported having been harmed or negatively affected in some way because of BZRA use. Several respondents expressed regret over ever taking BZRAs and/or reported that, with the benefit of hindsight, they should never have taken BZRAs in the first instance.
The findings highlight the range of barriers faced by those attempting BZRA discontinuation and the importance of additional supports. Holistic and person-centred approaches are needed to support discontinuation of long-term BZRA use that considers an individual's personal circumstances and wider social context. PATIENT OR PUBLIC CONTRIBUTION: 'Experts by experience' with previous experience of long-term BZRA use were involved in developing the questionnaire and writing the manuscript as collaborators. Individuals with lived experience of taking BZRAs completed the questionnaire.
全球许多人仍在长期(≥3 个月)服用苯二氮䓬受体激动剂(BZRAs)。本研究旨在对在线问卷调查中回复者的自由文本回复进行内容分析,以了解与长期 BZRA 停药相关的行为改变中介因素,从而了解他们停药的观点和经验。
该问卷通过在线 BZRA 支持小组向有当前或以前长期 BZRA 使用经验的社区成人发放。四个自由文本问题主要集中在(1)停药的障碍和(2)促进因素;(3)停药所需的额外支持;以及(4)关于 BZRA 使用的其他评论。使用总结性内容分析对回复数据进行分析。
报告的最常见停药障碍与停药的后果有关,包括戒断症状和原有症状复发的可能性。回复者报告的最常见促进因素是支持,主要来自医疗专业人员。许多回复者报告说,由于使用 BZRA,他们受到了伤害或产生了某种负面影响。一些回复者对曾经使用 BZRAs 表示遗憾,或表示有先见之明的话,他们一开始就不应该使用 BZRAs。
研究结果强调了试图停药的人所面临的一系列障碍,以及额外支持的重要性。需要采取整体和以个人为中心的方法来支持长期 BZRA 的停药,考虑到个人的个人情况和更广泛的社会背景。
有长期 BZRA 使用经验的“有经验的专家”参与了问卷的开发和协作撰写。有服用 BZRAs 经验的个人完成了问卷调查。